Pupillometric evaluation of α₁-adrenergic blockers in benign prostatic hyperplasia

Erdem Dursun; Ercan Yuvanç; Miraç Ataman; Oğuzhan Akça

doi:10.18614/dehm.1810162

Pupillometric evaluation of α₁-adrenergic blockers in benign prostatic hyperplasia

Abstract

Objectives: The purpose of this study was to evaluate the effects of adrenergic receptor antagonists on pupillary function in patients with benign prostatic hyperplasia (BPH) and to compare the pupillometric alterations between the A-selective blocker tamsulosin and the non-subtype-selective blocker doxazosin. Methods: This retrospective study included 158 men: 58 treated with tamsulosin, 46 with doxazosin, and 54 healthy controls. An automated quantitative pupillography system was used to measure pupillary responses in scotopic (0.04 lux), mesopic (4 lux), and photopic (50 lux) conditions, as well as during dynamic testing after the light was turned off. Demographic, clinical, and medication-related variables were recorded, and correlations between drug exposure duration, International Prostate Symptom Score (IPSS), and pupillometric parameters were analyzed. Results: Both α₁-blocker groups exhibited significantly smaller static and dynamic pupil diameters than controls (p < 0.001). Under scotopic conditions, the mean pupil diameter was 4.24 ± 0.72 mm in the tamsulosin group, 4.75 ± 1.17 mm in the doxazosin group, and 5.30 ± 1.03 mm in controls (p < 0.001 for overall comparison). The reduction was greater with tamsulosin than with doxazosin (p = 0.033). Dynamic pupillometry revealed consistently smaller pupil sizes at all time points in both drug groups, indicating impaired sympathetic dilator activity. No significant correlations were found between treatment duration, IPSS, and pupillometric outcomes. Conclusions: Tamsulosin and doxazosin both attenuate static and dynamic pupillary responses, suggesting reduced sympathetic control of the iris. The more pronounced scotopic constriction with tamsulosin supports its stronger α₁A-receptor affinity and provides quantitative evidence of its association with increased risk of intraoperative floppy iris syndrome. Quantitative pupillometry offers an objective preoperative tool for identifying α₁-blocker users at risk of poor pupil dilation during cataract surgery

Keywords

References

1. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31:664–73.
2. Chang DF, Campbell JR, Colin J, Schweitzer C. Prospective multicenter evaluation of floppy iris syndrome in cataract surgery. J Cataract Refract Surg. 2007;33:1227–1234.
3. Schwinn DA, Afshari NA. α₁-Adrenergic receptor antagonists and the iris: new mechanistic insights into floppy iris syndrome. Ophthalmology. 2006;113:1823–1829.
4. Lakhani M, Kwan ATH, Mihalache A, Popovic MM, Hurley B, Muni RH. Drugs Associated With Floppy Iris Syndrome: A Real-World Population-Based Study. Am J Ophthalmol. 2025; 275: 36-46.
5. Cheung CM, Awan MA, Sandramouli S. Prevalence and clinical findings of tamsulosin-associated intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2006;32:1336-1339.
6. Chang DF, Campbell JR, Colin J, Schweitzer C; Study Surgeon Group. Prospective masked comparison of intraoperative floppy iris syndrome severity with tamsulosin versus alfuzosin. Ophthalmology. 2014;121:829-834.
7. Chatziralli IP, Sergentanis TN. Risk factors for intraoperative floppy iris syndrome: a meta-analysis. Ophthalmology. 2011;118:730-735.
8. Ishikawa H, Miller DD, Patil PN. Comparison of post-junctional alpha-adrenoceptors in iris dilator muscle of humans, and albino and pigmented rabbits. Naunyn Schmiedebergs Arch Pharmacol. 1996;354:765-772.

9. Lepor H, Tang R, Meretyk S, Shapiro E. Alpha 1 adrenoceptor subtypes in the human prostate. J Urol. 1993;149:640-642.
10. Gani J, Perlis N, Radomski SB. Urologic medications and ophthalmologic side effects: a review. Can Urol Assoc J. 2012;6:53-58.
11. Mathôt S. Pupillometry: psychology, physiology, and function. J Cogn. 2018;1:16.
12. Tekin K, Sekeroglu MA, Kiziltoprak H, Doguizi S, Inanc M, Yilmazbas P. Static and dynamic pupillometry data of healthy individuals. Clin Exp Optom. 2018;101:659-665.
13. Karaca U, Kaya E, Ayyildiz O, Ozge G, Kucukevcilioglu M, Usta G, Mutlu FM. Evaluation of static and dynamic Pupillometry changes in men using Silodosin for benign prostatic hypertrophy. BMC Ophthalmol. 2021;21:125.
14. Altan-Yaycioglu R, Yaycioglu O, Gul U, Pelit A, Adibelli FM, Akova YA. The effects of two systemic alpha1-adrenergic blockers on pupil diameter: a prospective randomized single-blind study. Naunyn Schmiedebergs Arch Pharmacol. 2007;375:199-203.
15. Haridas A, Syrimi M, Al-Ahmar B, Hingorani M. Intraoperative floppy iris syndrome (IFIS) in patients receiving tamsulosin or doxazosin-a UK-based comparison of incidence and complication rates. Graefes Arch Clin Exp Ophthalmol. 2013;251:1541-1545.
16. Wang YH, Huang LC, Tsai SHL, Chen YJ, Wu CL, Kang YN. Risk of intraoperative floppy iris syndrome among selective alpha-1 blockers-A consistency model of 6,488 cases. Front Med (Lausanne). 2022;9:941130.
17. Kaushik J, Sharma R, Goyal S, Dangi M, Jha RK, Singh A. Alpha-adrenergic antagonists and iris dynamics: Challenges and solutions in cataract surgery. BMC Ophthalmol. 2024; 24:431.
18. Goseki T, Ishikawa H, Ogasawara S, Mashimo K, Nemoto N, Taguchi Y, et al. Effects of tamsulosin and silodosin on isolated albino and pigmented rabbit iris dilators: possible mechanism of intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2012; 38: 1643-1649.
19. Theodossiadis PG, Achtsidis V, Theodoropoulou S, Tentolouris N, Komninos C, Fountas KN. The effect of alpha antagonists on pupil dynamics: implications for the diagnosis of intraoperative floppy iris syndrome. Am J Ophthalmol. 2012;153:620-626.
20. Cooney TM, Wu A, Wilkes G, Finkelstein JI, Musch DC. The effects of systemic α₁-adrenoreceptor antagonists on pupil diameter. Br J Ophthalmol. 2012;96:490-493.

Details

Primary Language

English

Subjects

Urology, Clinical Sciences (Other)

Journal Section

Research Article

Authors

Erdem Dursun ^*
Türkiye

Ercan Yuvanç
0000-0002-5822-6972
Türkiye

Miraç Ataman
Türkiye

Oğuzhan Akça
Türkiye

Early Pub Date

April 29, 2026

Publication Date

April 29, 2026

Submission Date

October 24, 2025

Acceptance Date

February 22, 2026

Published in Issue

Year 2026 Volume: 40 Number: 2

DOI

https://doi.org/10.18614/dehm.1810162

IZ

https://izlik.org/JA77RD98KS

Cite

RIS / Bibtex

APA

Dursun, E., Yuvanç, E., Ataman, M., & Akça, O. (2026). Pupillometric evaluation of α₁-adrenergic blockers in benign prostatic hyperplasia. Developments and Experiments in Health and Medicine, 40(2), 220-227. https://doi.org/10.18614/dehm.1810162

AMA

1.Dursun E, Yuvanç E, Ataman M, Akça O. Pupillometric evaluation of α₁-adrenergic blockers in benign prostatic hyperplasia. Dev Exp Health Med. 2026;40(2):220-227. doi:10.18614/dehm.1810162

Chicago

Dursun, Erdem, Ercan Yuvanç, Miraç Ataman, and Oğuzhan Akça. 2026. “Pupillometric Evaluation of α₁-Adrenergic Blockers in Benign Prostatic Hyperplasia”. Developments and Experiments in Health and Medicine 40 (2): 220-27. https://doi.org/10.18614/dehm.1810162.

EndNote

Dursun E, Yuvanç E, Ataman M, Akça O (April 1, 2026) Pupillometric evaluation of α₁-adrenergic blockers in benign prostatic hyperplasia. Developments and Experiments in Health and Medicine 40 2 220–227.

IEEE

[1]E. Dursun, E. Yuvanç, M. Ataman, and O. Akça, “Pupillometric evaluation of α₁-adrenergic blockers in benign prostatic hyperplasia”, Dev Exp Health Med, vol. 40, no. 2, pp. 220–227, Apr. 2026, doi: 10.18614/dehm.1810162.

ISNAD

Dursun, Erdem - Yuvanç, Ercan - Ataman, Miraç - Akça, Oğuzhan. “Pupillometric Evaluation of α₁-Adrenergic Blockers in Benign Prostatic Hyperplasia”. Developments and Experiments in Health and Medicine 40/2 (April 1, 2026): 220-227. https://doi.org/10.18614/dehm.1810162.

JAMA

1.Dursun E, Yuvanç E, Ataman M, Akça O. Pupillometric evaluation of α₁-adrenergic blockers in benign prostatic hyperplasia. Dev Exp Health Med. 2026;40:220–227.

MLA

Dursun, Erdem, et al. “Pupillometric Evaluation of α₁-Adrenergic Blockers in Benign Prostatic Hyperplasia”. Developments and Experiments in Health and Medicine, vol. 40, no. 2, Apr. 2026, pp. 220-7, doi:10.18614/dehm.1810162.

Vancouver

1.Erdem Dursun, Ercan Yuvanç, Miraç Ataman, Oğuzhan Akça. Pupillometric evaluation of α₁-adrenergic blockers in benign prostatic hyperplasia. Dev Exp Health Med. 2026 Apr. 1;40(2):220-7. doi:10.18614/dehm.1810162